Alnylam Pharmaceuticals 주식 (NASDAQ: ALNY)

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

News

Movers

Trading Ideas

ALNY

COIN

MBLY

MRNA

RIVN

SMMT

STLA

FLSR

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?1. 휴마나(NYSE:HUM)가 별 등급의 2025년 실적 하락과 이것이 2026년 품질 보너스 지급에 어떤 영향을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 주가 예측을 낮췄다.

코인베이스, 나이키 및 모더나는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (9월 30일-10월 4일)

CHRW

COKE

CVNA

DASH

DXCM

EXAS

Laboratory Corporation Of America Holdings

PYPL

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 이그젝트 사이언스(NASDAQ:EXAS)가 예상보다 나은 2분기 재무 결과를 보고하고 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

Biotech

Equities

Large Cap

Sector ETFs

Health Care

Small Cap

Global

Exclusives

Tech

ETFs

ABBV

AMGN

HRTS

테마(Tema) ETFs의 설립자이자 CEO인 마우리츠 팟(Maurits Pot)은 비만 치료를 위한 GLP-1 약물 시장은 1조 달러 이상으로 급등할 것으로 예상된다고 벤징가(Benzinga)와의 독점 인터뷰에서 그의 낙관적인 예측을 공유했다. 

단독: GLP-1 체중 감량 약물은 수조 달러 규모의 시장 가능성, 테마 ETFs CEO의 전망

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies raised Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) price target from $105 to $118. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Wynn Resorts shares closed at $88.82 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WYNN/analyst-ratings">view </a>this stock.</li>
<li>Keefe, Bruyette &amp; Woods increased the price target for Brighthouse Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) from $60 to $66. Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintained a Market Perform rating. Brighthouse Financial shares closed at $62.14 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BHF/analyst-ratings">view </a>this stock.</li>
<li>Morgan Stanley raised Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $42 to $60. Morgan Stanley analyst Craig Hettenbach downgraded the stock from Overweight to Equal-Weight. Hims &amp; Hers Health shares closed at $60.47 on Friday. See how other <a href="https://www.benzinga.com/quote/HIMS/analyst-ratings">analysts </a>view this stock.</li>
<li>Needham raised the price target for DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) from $60 to $65. Needham analyst Bernie McTernan maintained a Buy rating. DraftKings shares closed at $53.49 on Friday. <a href="https://www.benzinga.com/quote/DKNG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised the price target for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from $41 to $47. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Bath &amp; Body Works shares closed at $36.47 on Friday. <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Outlook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) price target from $30 to $3. HC Wainwright &amp; Co. analyst Douglas Tsao maintained a Buy rating. Outlook Therapeutics shares settled at $1.87 on Friday. <a href="https://www.benzinga.com/quote/OTLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $384 to $385. Canaccord Genuity analyst Whitney Ijem maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $256.45 on Friday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $255 to $305. Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained a Market Perform rating. Coinbase shares closed at $274.31 on Friday.  <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) from $155 to $150. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Dell shares settled at $114.38 on Friday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank cut Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) price target from $128 to $105. Deutsche Bank analyst James Shin downgraded the stock from Buy to Hold. Merck shares closed at $83.01 on Friday. <a href="https://www.benzinga.com/quote/mrk/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

BBWI

Brighthouse Financial, Inc. - Common Stock

DELL

DKNG

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OTLK

WYNN

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $384 to $385.

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $385

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Equal-Weight and raises the price target from $275 to $284.

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $284

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

Reiteration

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Guidance

Alnylam Sees 2024 Total TTR Net Product Revenues $1.6B-$1.725B

Earnings

Alnylam Pharmaceuticals Q4 2024 Adj. EPS $0.06, Sales $593.166M Beat $583.791M Estimate

ABNB

AENT

AGIO

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

CROX

CYBR

DDOG

DNOW

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

In the latest quarter, 7 analysts provided ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alnylam Pharmaceuticals and provided 12-month price targets. The average target is $332.29, accompanied by a high estimate of $400.00 and a low estimate of $296.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.17%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300431_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Alnylam Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alnylam Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Alnylam Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Alnylam Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -33.26%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -22.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -761.91%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.72%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 5.7% since its last report. The company recently reported that it has 3.15 million shares sold short, which is 2.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739219412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Alnylam Pharmaceuticals's Recent Short Interest

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.34% on an annualized basis producing an average annual return of 20.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.14 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $16,726.61 today based on a price of $280.16 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738274415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 4.18% since its last report. The company recently reported that it has 3.35 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737032452_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 7.96% on an annualized basis producing an average annual return of 19.36%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.31 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $14,221.92 today based on a price of $258.27 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736802908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

WIIM

Alnylam Pharmaceuticals shares are trading higher. The company reported preliminary results.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.2, a high estimate of $400.00, and a low estimate of $296.00. This current average has increased by 2.93% from the previous average price target of $326.64. 
<img src="https://www.benzinga.com/files/images/story/2025/1736769643_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$371.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alnylam Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>A Deep Dive into Alnylam Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Alnylam Pharmaceuticals faced challenges, resulting in a decline of approximately -33.26% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -22.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.72%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

<ul>
<li>– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO&#xAE;, AMVUTTRA&#xAE;, GIVLAARI&#xAE;, and OXLUMO&#xAE;, Representing 33% Annual Growth –</li>
<li>– 2025 Combined Net Product Revenue Guidance&#x2A;&#x2A; of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability –</li>
<li>– Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth –</li>
</ul>

Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals

Bernstein analyst William Pickering maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and lowers the price target from $314 to $310.

Bernstein Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $310

Press Releases

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

GIVLAARI® (givosiran injection) Now Widely Reimbursed in Canada For the Treatment of Acute Hepatic Porphyria (AHP) in Adults

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Canaccord Genuity

Scotiabank

Morgan Stanley

Needham

RBC Capital

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)가 별 등급의 2025년 실적 하락과 이것이 <a href="https://www.benzinga.com//node/41140319" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2026년 품질 보너스 지급에 어떤 영향</a>을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 <a href="https://www.benzinga.com/quote/hum/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 낮췄다.
2. 스텔란티스 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)의 주가는 크라이슬러 모기업의 미국 판매가 <a href="https://www.benzinga.com//node/41147560" target="_blank" rel="noreferrer noopener">3분기에 20% 급락</a>했다고 발표한 후 17.06% 하락했다. <a href="https://www.benzinga.com//node/41190669" target="_blank" rel="noreferrer noopener">여러</a> 애널리스트들이 <a href="https://www.benzinga.com/quote/stla/analyst-ratings" target="_blank" rel="noreferrer noopener">주식을 하향 조정</a>했다.
3. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 10.63% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/41171878" target="_blank" rel="noreferrer noopener">MICA 유럽 규정을 충족하지 않는</a> 스테이블코인에 대한 서비스를 제한할 것이라고 발표했다.
4. 모빌아이 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>)의 주식은 10.15% 하락했다.
5. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)는 <a href="https://www.benzinga.com//node/41182921" target="_blank" rel="noreferrer noopener">R1 및 RCV 플랫폼의 공유 부품</a> 공급 부족으로 인해 회사가 연간 생산 지침을 낮춘 후 지난 주 주가는 10% 하락했다.
6. 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLSR#NASDAQ">FLSR</a>)의 주식은 9.63% 하락했다.
7. 콘아그라 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)의 주식은 <a href="https://www.benzinga.com//node/41140181" target="_blank" rel="noreferrer noopener">1분기 재무 실적이 예상보다 저조</a>하게 나타났다고 보고한 후 9.12% 하락했다.
8. 플로어 &amp; 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)의 주식은 8.81% 하락했다.
9. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주가는 8.59% 급락했다. 이 회사는 <a href="https://www.benzinga.com//node/41174110" target="_blank" rel="noreferrer noopener">2차 EGFRm 비소세포폐암(NSCLC) 대상 HARMONi 임상 3상 시험의 등록 완료</a>되었다고 발표했다.
10. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가는 8.44% 하락했다. 이 회사는 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)와 진행 중인 특허 침해 소송에서 <a href="https://www.benzinga.com//node/41169029" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">합의에 도달</a>했다.
11. 나이키(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) 주식은 여러 투자 은행들이 <a href="https://www.benzinga.com//node/41147332" target="_blank" rel="noreferrer noopener">1분기 매출 부진에 따라 목표 주가를 하향 조정</a>한 후 8.04% 하락했다.
또한 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A4%91%EA%B5%AD-%EC%A3%BC%EC%8B%9D%EC%9D%B4-%EC%A3%BC%EB%8F%84-%EB%A6%AC-%EC%98%A4%ED%86%A0%EC%99%80-jd%EB%8B%B7%EC%BB%B4%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1/" target="_blank" rel="noopener">미국에 상장된 중국 주식이 또 한 주를 장악 &#8211; 리 오토, JD닷이 지난 주 대형주 상승률 10위 안에 포함되다 (9월 30일~10월 4일): 다른 주식들은 당신의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: rafapress via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)가 예상보다 나은 2분기 재무 결과를 보고하고 <a class="ticker" href="https://www.benzinga.com//node/40085338" target="_blank" rel="noreferrer noopener">트윈스트랜드 바이오사이언스(TwinStrand Biosciences)</a>와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/exas/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측</a>을 하향 조정했다.</li>
<li>앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)가 예상보다 나은 2분기 재무 실적을 발표한 후 주가는 15.35% 상승했다. 애널리스트들은 각자의 <a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>레즈메드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>)의 주가는 예상보다 나은 4분기 실적을 보고하고 <a href="https://www.benzinga.com//node/40133504" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 배당금을 인상</a>한 후 10.09% 상승했다. 몇몇 분석가들도 주식 가격 예측을 높였다.</li>
<li>코카콜라 콘솔리데이티드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>)의 주가는 회사가 2분기 재무 실적이 <a href="https://www.benzinga.com//node/40081001" target="_blank" rel="noreferrer noopener">전년 대비 증가</a>했다고 보고한 후 12.21% 상승했다.</li>
<li>덱스콤(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)의 주식은 지난주 11.18% 상승하여, 52주 최저점에서 반등했다.</li>
<li>스프라우츠 파머스 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)의 주가는 회사가 예상보다 나은 2분기 재무 실적을 보고하고 예상치를 웃도는 3분기 실적 가이던스를 발표한 후 11.87% 상승했습니다. 많은 분석가들이 회사의 <a href="https://www.benzinga.com//node/40048771" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가</a>를 높였다.</li>
<li>UL 솔루션즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>)가 <a href="https://www.benzinga.com//node/40063544" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 발표한 후 주가는 11.74% 상승했다.</li>
<li>랩코프 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>)의 주가는 예상보다 나은 2분기 재무 실적을 보고하고 FY24 매출 가이던스를 예상치보다 높인 후 11.34% 상승했다. 몇몇 분석가들은 회사에 대한 <a href="https://www.benzinga.com//node/40135030" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 예측</a>을 높였다.</li>
<li>C.H. 로빈슨 월드와이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)의 주가는 예상보다 나은 2분기 조정 EPS 실적을 발표한 후 10.98% 상승했다. 다수의 기업도 각각의 <a href="https://www.benzinga.com/quote/chrw/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>도어대시(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)가 <a href="https://www.benzinga.com//node/40116158" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 매출</a>을 보고한 후 주가는 10.24% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 높였다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%eb%a7%88%ec%9d%b4%ed%81%ac%eb%a1%9c%ec%8a%a4%ed%8a%b8%eb%a0%88%ed%8b%b0%ec%a7%80-%eb%b0%8f-%ec%9d%b8%ed%85%94%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">마이크로스트레티지 및 인텔은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 28일-8월 3일</a><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the">)</a></li>
</ul>
사진 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

테마(Tema) ETFs의 설립자이자 CEO인 마우리츠 팟(Maurits Pot)은 비만 치료를 위한 GLP-1 약물 시장은 1조 달러 이상으로 급등할 것으로 예상된다고 <a href="https://www.benzinga.com/exclusives">벤징가(Benzinga)와의 독점 인터뷰</a>에서 그의 낙관적인 예측을 공유했다. 
마우리츠는 &#8220;장기적으로 이것은 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 사이의 양대 경쟁이 아니라고 생각한다&#8221;고 말하며, 체중 감량 시장에서 널리 퍼져 있는 두개의 기업이 전체 시장을 과점(duopoly)하는 개념에 도전했다.
Pot은 체중 감량 치료제에 대한 수요 증가와 GLP-1 약물의 적용 확대가 이 1조 달러 규모의 시장 기회를 주도할 것이라고 예측한다.
2023년 11월, 테마 ETFs는 체중 감량에 초점을 맞춘 최초의 ETF인 Tema GLP-1, Obesity and Cardiometabolic ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>)를 출시했다. SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)에서 추적한 바와 같이, 이 펀드는 개시 이후 25% 상승하여 S&amp;P 500의 성과를 약간 앞섰다.
이 ETF의 주요 보유 종목으로는 일라이 릴리, 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), 노보 노디스크, 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)가 있으며 각각 약 5~6%의 비중을 갖고 있다. 이 HRTS 포트폴리오는 또한 40개 이상의 기타 체중 감량 관련 회사들로 구성되어 있다.
차트: Tema GLP-1, Obesity and Cardiometabolic ETF는 설정 이후 S&amp;P 500을 능가
<figure class="wp-block-image size-large"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-422177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1024x652.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1024x652.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-300x191.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-768x489.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10-1536x978.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/05152109/image-10.png 1662w" alt="" width="1024" height="652" /></a></figure>
차트: <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070524&amp;t=be2bearmibe3na1">벤징가 프로</a> 
<h3 class="wp-block-heading">체중 감량 치료: 응용 분야 및 혁신 확대</h3>
팟(Pot)에 따르면, GLP-1 약물은 곧 체중 감량을 넘어 당뇨병, 심장, 간 및 신장 질환에 적용되고 암, 알츠하이머병, 파킨슨병 및 기타 신경성 질환과 같은 질환을 치료할 수 있는 가능성이 있다고 한다.
기존 주사 방법은 경구 투여 또는 투여 빈도 감소에 초점을 맞춘 새로운 접근법으로 인해 어려움을 겪고 있다. 혁신의 목표는 주 1회 주사에서 잠재적으로 2개월에 한 번으로 전환하는 등 치료법을 덜 침습적으로 만들거나 경구 정제 생산과 같이 제조하기를 훨씬 쉽게 만드는 것이다.
비만은 당뇨병, 심장병, 암 등 다양한 질병을 유발한다. 따라서 비만을 해결하면 여러 가지 건강 문제를 완화하고 GLP-1 약물의 시장 잠재력을 증폭시킬 수 있다.
이 시장은 일라이 릴리 및 노보 노디스크를 넘어 다양한 질병 영역을 다루게 될 것으로 예상된다.
팟은 비만, 당뇨병, 잠재적으로 알츠하이머병이나 암에 대한 용도를 언급하면서 &#8220;세계 인구의 절반이 GLP-1이나 다른 체중 감량 약물을 1차 예방 등의 다른 이유로 복용하는 세상을 볼 수 있다&#8221;라고 말했다.
<h3 class="wp-block-heading">1조 달러 예상의 배경</h3>
전 세계 비만 인구는 2035년까지 10억 명에서 20억 명으로 두 배로 늘어날 것으로 예상된다. 이러한 성장이 없더라도 기존 10억 명의 비만 인구는 상당한 시장을 대표한다.
장기 치료가 현재 비만 인구의 20%에게만 도달한다면, 이는 현재 당뇨병 약물의 보급률과 유사하게 2억 명에 해당한다. 연간 1인당 약가가 12,000달러에서 6,000달러로 인하된다고 가정하면 GLP-1 의약품 시장은 1조 달러를 넘어설 수 있다고 팟이 설명했다.
골드만삭스는 시장 규모를 1,000억~1,300억 달러로 추정하지만 팟은 암, 알츠하이머병, 파킨슨병에 대한 투기적 적용을 고려하기 전에도 시장이 1조 달러에 도달할 수 있다고 믿고 있다. 시장 규모는 지속적으로 과소평가되어 왔으며 추정치는 몇 달마다 증가하고 있다.
특허 만료는 또한 시장을 형성할 것이다. 미국에서는 오젬픽(Ozempic)/위고비(Wegovy)의 특허가 2032년에 만료되고, 유럽에서는 2031년, 중국에서는 2026년에 만료된다.
"특허가 만료되기 전에는 1조 달러 규모의 시장이 될 것이라고 생각한다"라고 팟은 말했다.
<h3 class="wp-block-heading">중소형주에 초점 맞추기</h3>
왜 투자자들이 소수의 대형주 대신 다양한 체중 감량 관련 주식에 집중해야 하는지 묻는 질문에 팟은 일라이 릴리와 같은 대기업들과 달리 &#8220;이 거대한 중소형 생명공학 시장에서 긍정적인 임상 결과의 영향이 훨씬 더 높다&#8221;고 설명했다. 
그는 포트폴리오 균형으로 대형주를 보유하는 것의 중요성을 강조했지만 소규모 회사들이 장기적으로 더 높은 수익을 제공할 수 있다고 지적했다.
팟은 생명공학 부문이 인수합병으로 성숙해 있음을 강조했다. 지난해에만 가치가 10억 달러를 초과하는 생명공학 M&amp;A 거래가 22건 있었다.
머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), 또는 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 같이 비만 사업이 없는 주요 헬스케어 회사들이 인수를 모색할 가능성이 높다.
지금 읽기
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/06/39143220/exclusive-tema-american-reshoring-etf-outshines-s-p-500-without-owning-magnificent-7-stocks-they-can">단독: Tema American Reshoring ETF는 7개 주식을 보유하지 않고도 S&amp;P 500을 능가</a></li>
</ul>
사진: 셔터스톡


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

6월은 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener" data-google-interstitial="false">섹터 및 산업 성과</a>의 상당한 격차에도 불구하고 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500이 3.2% 상승하는 등 주식 시장에서 높은 평가를 받으며 마감되었다.
Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)가 추적하는 기술 부문은 지난달 실적에서 11개 S&amp;P 500 섹터를 주도하며 7.7% 급등해 올해 가장 높은 월간 상승률을 달성했다.
이와는 대조적으로 유틸리티 부문은 Utilities Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)가 6.3% 하락해 2023년 9월 이후 최악의 달을 기록하는 등 부진했다.
<h3 class="wp-block-heading">6월 최고의 성과를 보인 산업 ETF들</h3>
iShares Expanded Tech-Software Sector ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGV#NYSE">IGV</a>)는 지난달 11.3% 상승하여 산업 ETF 중 1위를 차지했다.
이에 뒤이어 VanEck Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>)가 8.4% 상승하며 반도체 부문에서 강력한 모멘텀을 보여주었다.
VanEck Semiconductor ETF는 2023년 10월 최저치를 기록한 이후 무려 87%, 2022년 10월 이후로는 200% 이상 상승해 AI 중심 주식의 눈부신 성장을 반영했다.
월간 실적 측면에서 3위를 차지한 SPDR S&amp;P Biotech ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)는 4% 상승했다.
소프트웨어 부문에서는 24.9% 상승한 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), 22.1% 오른 크라우드스트라이크 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), 20% 상승한 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)이 눈에 띄는 성과를 거두었다.
브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)는 21% 상승으로 칩 제조업체를 이끌었다. 유니버설 디스플레이 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NYSE">OLED</a>)은 19.7% 증가로 그 뒤를 쫓았고, 코보(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)는 18% 상승을 기록했다.
생명공학 분야에서 실렉스 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>)는 78.8%의 급등을 경험하여 업계 최고의 상승세를 보였다. 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)는 63.7% 급등한 반면, 어비디티 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)는 52%의 강력한 상승세를 보였다.
<h3 class="wp-block-heading">6월 자금 유입량 상위 산업 ETF</h3>
자금 흐름을 조사한 결과 VanEck Semiconductor ETF는 투자자들에게 최고의 선택으로 부상했으며 트레이딩뷰(Tradingview) 데이터에 따르면 10억 달러 이상을 유치하고 9개월 연속 유입을 달성했다. 올해 현재까지 이 펀드는 46억 달러의 순유입을 기록했다.
iShares Expanded Tech-Software Sector ETF는 6월에 약 4억 8천만 달러를 유치하여 6개월 연속 유출을 깨고 2022년 9월 이후 가장 높은 월간 유입을 기록했다. 그러나 연간 순 흐름은 여전히 ​​11억 5천만 달러 마이너스이다.
iShares Biotechnology ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NYSE">IBB</a>)는 투자자들의 높은 관심을 반영하여 지난달 1억 4,800만 달러의 자금을 유입했다. 강력한 유입을 목격한 또 다른 업계는 약 1억 3천만 달러를 유치한 Global X Copper Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>)로 대표된다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39577080/manufacturing-contracts-more-than-expected-in-june-putting-pressure-on-profitabilit">6월 제조업 계약 예상보다 많아 &#8216;수익성 압박&#8217;: 수익률 상승, 주식 하락</a></li>
</ul>
사진: 셔터스톡

Broad U.S. Equity ETFs

6월 상위 성과 업종 ETF: 소프트웨어는 수익을 선도, 칩 메이커들은 가장 많은 자금 유치

Comments

Alnylam Pharmaceuticals

뉴스

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

일요일, 10월 06, 2024

일요일, 8월 04, 2024

일요일, 7월 07, 2024

화요일, 7월 02, 2024

일요일, 6월 30, 2024

화요일, 6월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌